176 related articles for article (PubMed ID: 37798436)
1. Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients.
Ferreira AMC; Altemani JMC; Macedo LT; Lourenço GJ; Lima CSP
Sci Rep; 2023 Oct; 13(1):16762. PubMed ID: 37798436
[TBL] [Abstract][Full Text] [Related]
2. GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract][Full Text] [Related]
3. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Lopes-Aguiar L; Costa EF; Nogueira GA; Lima TR; Visacri MB; Pincinato EC; Calonga L; Mariano FV; de Almeida Milani Altemani AM; Altemani JM; Coutinho-Camillo CM; Ribeiro Alves MA; Moriel P; Ramos CD; Chone CT; Lima CS
Oncotarget; 2017 Mar; 8(10):16190-16201. PubMed ID: 26918827
[TBL] [Abstract][Full Text] [Related]
4.
Costa EFD; Lima TRP; Lopes-Aguiar L; Nogueira GAS; Visacri MB; Quintanilha JCF; Pincinato EC; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
Tumour Biol; 2020 Jul; 42(7):1010428320938494. PubMed ID: 32628088
[TBL] [Abstract][Full Text] [Related]
5. Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study.
Macedo LT; Costa EFD; Carvalho BF; Lourenço GJ; Calonga L; Castilho AM; Chone CT; Lima CSP
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980643
[TBL] [Abstract][Full Text] [Related]
6. Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma.
Nogueira GA; Lourenço GJ; Oliveira CB; Marson FA; Lopes-Aguiar L; Costa EF; Lima TR; Liutti VT; Leal F; Santos VC; Rinck-Junior JA; Lima CS
Int J Cancer; 2015 Aug; 137(4):810-8. PubMed ID: 25598504
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients.
Nogueira GAS; Costa EFD; Lopes-Aguiar L; Lima TRP; Visacri MB; Pincinato EC; Lourenço GJ; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
Oncotarget; 2018 Jul; 9(51):29538-29547. PubMed ID: 30038702
[TBL] [Abstract][Full Text] [Related]
8. GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.
Pincinato EC; Costa EFD; Lopes-Aguiar L; Nogueira GAS; Lima TRP; Visacri MB; Costa APL; Lourenço GJ; Calonga L; Mariano FV; Altemani AMAM; Coutinho-Camillo C; Chone CT; Ramos CD; Altemani JMC; Moriel P; Lima CSP
Sci Rep; 2019 Jun; 9(1):9312. PubMed ID: 31249357
[TBL] [Abstract][Full Text] [Related]
9. Influence of CASP9 c.-1339A>G and CASP3 c.-1191A>G variants in outcome of patients with head and neck squamous cell carcinoma.
Carvalho BF; Costa EFD; Lopes-Aguiar L; Liutti VT; Leal F; Vasconcelos VCA; Rinck-Junior JA; Lourenço GJ; Lima CSP
J Oral Pathol Med; 2020 Nov; 49(10):1078-1083. PubMed ID: 32816327
[TBL] [Abstract][Full Text] [Related]
10. The DNA damage response network in the treatment of head and neck squamous cell carcinoma.
Psyrri A; Gkotzamanidou M; Papaxoinis G; Krikoni L; Economopoulou P; Kotsantis I; Anastasiou M; Souliotis VL
ESMO Open; 2021 Apr; 6(2):100075. PubMed ID: 33714009
[TBL] [Abstract][Full Text] [Related]
11. DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck.
Farnebo L; Stjernström A; Fredrikson M; Ansell A; Garvin S; Thunell LK
DNA Repair (Amst); 2015 Jul; 31():64-72. PubMed ID: 26001739
[TBL] [Abstract][Full Text] [Related]
12. Do genetic polymorphisms modulate response rate and toxicity of Cisplatin associated with radiotherapy in laryngeal squamous cell carcinoma?: a case report.
Lopes-Aguiar L; Visacri MB; Nourani CML; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Moriel P; Altemani JMC; Lima CSP
Medicine (Baltimore); 2015 Apr; 94(16):e578. PubMed ID: 25906090
[TBL] [Abstract][Full Text] [Related]
13. CASP9 c.-1339A>G and CASP3 c.-1191A>G polymorphisms alter susceptibility and clinical aspects of head and neck squamous cell carcinoma.
Costa EFD; Lopes-Aguiar L; Nogueira GS; Lima TRP; Rinck-Junior JA; Lourenço GJ; Lima CSP
Head Neck; 2019 Aug; 41(8):2665-2670. PubMed ID: 30903678
[TBL] [Abstract][Full Text] [Related]
14. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
15. Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types).
Nouman M; Haider G; Bukhari N; Yousuf A; Nouman R; Shaikh MR; Hussain S; Pavan B; Rahool R; Memon P; Zahoor S; Mehar K; Sami A
Asian Pac J Cancer Prev; 2020 Mar; 21(3):825-830. PubMed ID: 32212813
[TBL] [Abstract][Full Text] [Related]
16. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
Bănescu C; Iancu M; Trifa AP; Dobreanu M; Moldovan VG; Duicu C; Tripon F; Crauciuc A; Skypnyk C; Bogliș A; Lazar E
Tumour Biol; 2016 Jul; 37(7):9357-66. PubMed ID: 26779634
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
[TBL] [Abstract][Full Text] [Related]
20. Associated risk of XRCC1 and XPD cross talk and life style factors in progression of head and neck cancer in north Indian population.
Kumar A; Pant MC; Singh HS; Khandelwal S
Mutat Res; 2012 Jan; 729(1-2):24-34. PubMed ID: 21945240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
